ReviewFrontiers in immunology2021
Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta-analysis of ocular immune-related adverse events.Acta ophthalmologica · 2026Pooled it
- Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings.International journal of clinical oncology · 2026Review
- Immune Checkpoint Inhibitor-Induced Vogt-Koyanagi-Harada-like Disease Complicated by Inflammatory Macular Neovascularisation: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Ophthalmic Immune-Related Adverse Events in Cancer Immunotherapy: Tissue-Specific Mechanisms, Clinical Phenotypes, and Consensus-Based Management.International journal of molecular sciences · 2026Review
- [Corneal melting under PD-1/PD-L1 inhibition].Die Ophthalmologie · 2026Article
- Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody-Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization.Pharmaceutical research · 2026Review
- Case report: Vogt-Koyanagi-Harada-like uveitis induced by anti-PD-1 therapy (Sintilimab) in a gastric cancer patient: a case study.Frontiers in pharmacology · 2026Article
- Comprehensive safety analysis of the clinical spectrum of adverse events associated with immune checkpoint inhibitors based on FAERS.Frontiers in immunology · 2026Article
- The application and challenges of immune checkpoint inhibitors in lung cancer therapy.Frontiers in immunology · 2026Review
- Immunotherapy-induced sialadenitis: sjögren's syndrome or a new sialadenitis.Frontiers in immunology · 2026Article
- Review
- Single-Cell Transcriptomics Reveals a Multi-Compartmental Cellular Cascade Underlying Elahere-Induced Ocular Toxicity in Rats.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer.Nature reviews. Clinical oncology · 2025Review
- Mechanistic Insights into Anti-Nectin4-VcMMAE-Induced Ocular Toxicity: From Cellular Uptake Pathways to Molecular Modification.International journal of molecular sciences · 2025Article
- Clinical features, treatment, and outcomes of nivolumab induced psoriasis.Investigational new drugs · 2025Article
- Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products.Frontiers in immunology · 2025Review
- Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database.American journal of ophthalmology · 2024Article
- Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review.Biomedicines · 2024Review
- Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis.Investigational new drugs · 2024Article
- Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.BMC ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are novel immunotherapy-based drugs that have become increasingly popular in the treatment of lung cancer. Researchers have recognized ocular immune-related adverse events (irAEs) secondary to ICIs because of their vision-threatening characteristics. However, they are incompletely characterized and no studies have reported the ICI-related ocular irAEs in lung cancer. Therefore, we aimed to comprehensively illustrate the clinical characteristics, contributory factors, diagnosis, and management of ICI-related ocular irAEs in lung cancer, based on previously reported 79 patients. Ophthalmoplegia (40.51%), uveitis (20.25%), and dry eye (17.72%) were the most common ICI-related ocular irAEs in lung cancer. Ptosis was the most common (36.71%) and the highest mortality (23.33%) of ophthalmoplegia. Patients in Asia and patients who underwent combination therapy with programmed cell death-1 and cytotoxic T-lymphocyte-associated antigen 4 inhibitors demonstrated significantly higher frequency of ophthalmoplegia than other ocular irAEs. Most ICI-related ophthalmoplegia and uveitis in lung cancer were observed in the first 10 weeks following the initiation of ICIs. Furthermore, the onset time of dry eye and other ocular irAEs was much longer. In addition, 92.31% of the patients with ocular irAEs other than ophthalmoplegia could be remised. In conclusion, ocular irAEs secondary to ICIs in lung cancer are non-negligible, particularly ophthalmoplegia. Ethnicity and the type of ICIs play important roles in the distribution of ocular irAEs. ICI-related ophthalmoplegia in lung cancer presented with early onset and worse prognosis features, thus necessitating further attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.